Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo S Hoffmeyer, O Burk, O Von Richter, HP Arnold, J Brockmöller, A Johne, ... Proceedings of the National Academy of Sciences 97 (7), 3473-3478, 2000 | 3370 | 2000 |
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. C Sachse, J Brockmöller, S Bauer, I Roots American journal of human genetics 60 (2), 284, 1997 | 1357 | 1997 |
Functional significance of a C→ A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine C Sachse, J Brockmöller, S Bauer, I Roots British journal of clinical pharmacology 47 (4), 445-449, 1999 | 960 | 1999 |
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response J Kirchheiner, K Nickchen, M Bauer, ML Wong, J Licinio, I Roots, ... Molecular psychiatry 9 (5), 442-473, 2004 | 956 | 2004 |
Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects I Cascorbi, T Gerloff, A Johne, C Meisel, S Hoffmeyer, M Schwab, ... Clinical Pharmacology & Therapeutics 69 (3), 169-174, 2001 | 930 | 2001 |
Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) A Johne, J Brockmöller, S Bauer, A Maurer, M Langheinrich, I Roots Clinical Pharmacology & Therapeutics 66 (4), 338-345, 1999 | 815 | 1999 |
CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages J Kirchheiner, K Brøsen, ML Dahl, LF Gram, S Kasper, I Roots, F Sjöqvist, ... Acta Psychiatrica Scandinavica 104 (3), 173-192, 2001 | 567 | 2001 |
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication J Kirchheiner, H Schmidt, M Tzvetkov, J Keulen, J Lötsch, I Roots, ... The pharmacogenomics journal 7 (4), 257-265, 2007 | 547 | 2007 |
Combined Analysis of Inherited Polymorphisms in Arylamine N-Acetyltransferase 2, Glutathione S-Transferases M1 and T1, Microsomal Epoxide Hydrolase, and … J Brockmöller, I Cascorbi, R Kerb, I Roots Cancer Research 56 (17), 3915-3925, 1996 | 475 | 1996 |
A C4887A Polymorphism in Exon 7 of Human CYP1A1: Population Frequency, Mutation Linkages, and Impact on Lung Cancer Susceptibility I Cascorbi, J Brockmöller, I Roots Cancer research 56 (21), 4965-4969, 1996 | 457 | 1996 |
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population EA Gaikovitch, I Cascorbi, PM Mrozikiewicz, J Brockmöller, R Frötschl, ... European journal of clinical pharmacology 59, 303-312, 2003 | 448 | 2003 |
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis M Schwab, E Schaeffeler, C Marx, MF Fromm, B Kaskas, J Metzler, ... Gastroenterology 124 (1), 26-33, 2003 | 435 | 2003 |
Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. I Cascorbi, N Drakoulis, J Brockmöller, A Maurer, K Sperling, I Roots American journal of human genetics 57 (3), 581, 1995 | 430 | 1995 |
Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene A Johne, K Köpke, T Gerloff, I Mai, S Rietbrock, C Meisel, S Hoffmeyer, ... Clinical Pharmacology & Therapeutics 72 (5), 584-594, 2002 | 419 | 2002 |
Critical evaluation of the effect of valerian extract on sleep structure and sleep quality F Donath, S Quispe, K Diefenbach, A Maurer, I Fietze, I Roots Pharmacopsychiatry 33 (02), 47-53, 2000 | 370 | 2000 |
Reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent formation and breakdown of hydrogen peroxide during mixed function oxidation reactions in liver microsomes AG Hildebrandt, I Roots Archives of Biochemistry and Biophysics 171 (2), 385-397, 1975 | 368 | 1975 |
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin S Aynacioglu, J Brockmöller, S Bauer, C Sachse, P Güzelbey, Z Öngen, ... British journal of clinical pharmacology 48 (3), 409-415, 1999 | 354 | 1999 |
Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics J Mwinyi, A Johne, S Bauer, I Roots, T Gerloff Clinical Pharmacology & Therapeutics 75 (5), 415-421, 2004 | 349 | 2004 |
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6 J Kirchheiner, C Klein, I Meineke, J Sasse, UM Zanger, TE Mürdter, ... Pharmacogenetics and Genomics 13 (10), 619-626, 2003 | 317 | 2003 |
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes R Kaiser, O Sezer, A Papies, S Bauer, C Schelenz, PB Tremblay, ... Journal of Clinical Oncology 20 (12), 2805-2811, 2002 | 317 | 2002 |